Entain Valuation

Is ENT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ENT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ENT (£7.55) is trading below our estimate of fair value (£17.5)

Significantly Below Fair Value: ENT is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ENT?

Key metric: As ENT is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ENT. This is calculated by dividing ENT's market cap by their current revenue.
What is ENT's PS Ratio?
PS Ratio	1x
Sales	UK£4.91b
Market Cap	UK£4.83b

ENT key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.8x
Enterprise Value/EBITDA	10.7x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does ENT's PS Ratio compare to its peers?

The above table shows the PS ratio for ENT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	1x
PTEC Playtech	1.5x	3.1%	UK£2.2b
RNK Rank Group	0.6x	5.8%	UK£416.9m
EVOK Evoke	0.1x	5.9%	UK£241.4m
WTB Whitbread	1.7x	3.6%	UK£5.1b
ENT Entain	1x	4.5%	UK£4.8b

Price-To-Sales vs Peers: ENT is good value based on its Price-To-Sales Ratio (1x) compared to the peer average (1x).

Price to Sales Ratio vs Industry

How does ENT's PS Ratio compare vs other companies in the GB Hospitality Industry?

6 Companies	Price / Sales	Estimated Growth	Market Cap
EVOK Evoke	0.1x	5.9%	US$304.34m
TRC Revel Collective	0.06x	-3.1%	US$10.86m
NGHT Nightcap	0.1x	n/a	US$8.62m
TAST Tasty	0.05x	-15.3%	US$2.74m

6 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: ENT is good value based on its Price-To-Sales Ratio (1x) compared to the UK Hospitality industry average (1.1x).

Price to Sales Ratio vs Fair Ratio

What is ENT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ENT PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	1x
Fair PS Ratio	3x

Price-To-Sales vs Fair Ratio: ENT is good value based on its Price-To-Sales Ratio (1x) compared to the estimated Fair Price-To-Sales Ratio (3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ENT forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	UK£7.55	UK£9.59 +27.0%	11.9%	UK£11.40	UK£7.80	n/a	18
Nov ’25	UK£7.34	UK£9.59 +30.5%	12.0%	UK£11.40	UK£7.80	n/a	18
Oct ’25	UK£7.70	UK£9.30 +20.7%	14.7%	UK£11.40	UK£6.80	n/a	18
Sep ’25	UK£6.46	UK£9.41 +45.7%	15.2%	UK£11.40	UK£6.10	n/a	18
Aug ’25	UK£5.55	UK£10.05 +81.0%	13.5%	UK£11.85	UK£7.75	n/a	18
Jul ’25	UK£6.30	UK£10.14 +61.0%	12.5%	UK£11.85	UK£7.75	n/a	18
Jun ’25	UK£6.75	UK£10.19 +50.9%	11.7%	UK£11.85	UK£7.75	n/a	18
May ’25	UK£7.85	UK£10.35 +31.9%	13.1%	UK£13.30	UK£7.75	n/a	19
Apr ’25	UK£7.97	UK£10.47 +31.3%	13.8%	UK£13.30	UK£7.90	n/a	18
Mar ’25	UK£9.17	UK£11.68 +27.4%	12.6%	UK£14.20	UK£8.60	n/a	19
Feb ’25	UK£9.83	UK£11.63 +18.4%	13.3%	UK£14.20	UK£8.20	n/a	19
Jan ’25	UK£9.94	UK£12.02 +20.9%	16.2%	UK£16.00	UK£8.20	n/a	19
Dec ’24	UK£8.08	UK£12.73 +57.6%	18.0%	UK£16.40	UK£8.20	n/a	19
Nov ’24	UK£9.40	UK£14.84 +57.8%	12.9%	UK£19.30	UK£11.00	UK£7.34	19
Oct ’24	UK£9.33	UK£16.24 +74.1%	11.4%	UK£21.50	UK£13.00	UK£7.70	18
Sep ’24	UK£11.54	UK£17.94 +55.6%	12.6%	UK£22.00	UK£14.10	UK£6.46	18
Aug ’24	UK£13.81	UK£18.33 +32.7%	12.4%	UK£22.00	UK£14.10	UK£5.55	19
Jul ’24	UK£12.72	UK£18.47 +45.2%	12.9%	UK£23.00	UK£13.90	UK£6.30	19
Jun ’24	UK£13.19	UK£19.01 +44.2%	11.9%	UK£23.00	UK£13.90	UK£6.75	17
May ’24	UK£14.44	UK£18.59 +28.7%	10.9%	UK£21.80	UK£13.90	UK£7.85	18
Apr ’24	UK£12.57	UK£19.08 +51.8%	9.4%	UK£22.60	UK£15.60	UK£7.97	17
Mar ’24	UK£13.63	UK£19.06 +39.9%	11.1%	UK£22.70	UK£14.50	UK£9.17	18
Feb ’24	UK£15.01	UK£18.91 +26.0%	11.1%	UK£22.70	UK£14.50	UK£9.83	18
Jan ’24	UK£13.22	UK£18.48 +39.8%	13.5%	UK£22.70	UK£13.50	UK£9.94	18
Dec ’23	UK£14.03	UK£18.47 +31.6%	13.4%	UK£22.70	UK£13.50	UK£8.08	18
Nov ’23	UK£12.93	UK£18.38 +42.2%	12.9%	UK£22.40	UK£13.50	UK£9.40	17

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.